Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

NCT07140016 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT07140016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07140016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 22, 2025
Completion date
December 31, 2029
Enrollment
40 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase (alk) positive, non-small cell lung cancer (nsclc)